Skip to main content
Top
Published in: Globalization and Health 1/2017

Open Access 01-12-2017 | Research

Corporate social responsibility to improve access to medicines: the case of Brazil

Authors: Halla Thorsteinsdóttir, Natasha Ovtcharenko, Jillian Clare Kohler

Published in: Globalization and Health | Issue 1/2017

Login to get access

Abstract

Background

Access to medicines and the development of a strong national pharmaceutical industry are two longstanding pillars of health policy in Brazil. This is reflected in a clear emphasis by Brazil’s Federal Government on improving access to medicine in national health plans and industrial policies aimed at promoting domestic pharmaceutical development. This research proposes that such policies may act as incentives for companies to pursue a strategic Corporate Social Responsibility (CSR) agenda. CSR that supports Governmental priorities could help companies to benefit significantly from the Governmental industrial policy. We sought to determine whether CSR activities of Brazilian pharmaceutical firms are currently aligned with the Federal Government’s health prioritization. To do so we examined key Brazilian health related policies since 2004, including the specific priorities of Brazil’s 2012–2015 Health Plan, and compared these with CSR initiatives that are reported on the websites of select pharmaceutical firms in Brazil.

Results

Brazil’s national health plans and industrial policies demonstrated that the Federal Government has followed diverse approaches for improving access to medicines, including strengthening health care infrastructure, increasing transparency, and supporting product development partnerships. Case studies of six pharmaceutical firms, representing both public and private companies of varying size, support the perspective that CSR is a priority for firms. However, while many programs target issues such as health infrastructure, health care training, and drug donation, more programs focus on areas other than health and do not seem to be connected to Governmental prioritization.

Conclusion

This research suggests that there are loose connections between Governmental priorities and pharmaceutical firm CSR. However, there remains a significant opportunity for greater alignment, which could improve access to medicines in the country and foster a stronger relationship between the Government and industry.
Literature
1.
go back to reference Gadelha CAG, Costa LS, Maldonado JM, Barbosa PR, Vargas MA. The health care economic-industrial complex: Concepts and general characteristics. Health. 2013;10:1607–21.CrossRef Gadelha CAG, Costa LS, Maldonado JM, Barbosa PR, Vargas MA. The health care economic-industrial complex: Concepts and general characteristics. Health. 2013;10:1607–21.CrossRef
2.
go back to reference Shadlen KC, da Fonesca EM. Health policy as industrial policy: Brazil comparative perspective. Polit Soc. 2013;4:561–87.CrossRef Shadlen KC, da Fonesca EM. Health policy as industrial policy: Brazil comparative perspective. Polit Soc. 2013;4:561–87.CrossRef
3.
go back to reference Nacimento VM, Antonino PHD, Rezende KS, Bisinoti NVM, Olveira EJV, Paiva LB, Gadelha CAG. Brazilian industrial and innovation complex in health: Productive development partnerships (PDP) to guarantee access to health technologies in Brazil. Geneva: World Health Organization; 2014. Nacimento VM, Antonino PHD, Rezende KS, Bisinoti NVM, Olveira EJV, Paiva LB, Gadelha CAG. Brazilian industrial and innovation complex in health: Productive development partnerships (PDP) to guarantee access to health technologies in Brazil. Geneva: World Health Organization; 2014.
4.
go back to reference Bolton SC, Kim RC, O’Gorman KD. Corporate Social Responsibility as a dynamic internal organization process: a case study. J Bus Ethics. 2011;101(1):61–74.CrossRef Bolton SC, Kim RC, O’Gorman KD. Corporate Social Responsibility as a dynamic internal organization process: a case study. J Bus Ethics. 2011;101(1):61–74.CrossRef
5.
go back to reference Victora CG, Barreto M, Do Carmo Leal M, Monteiro CA, Ines-Schmidt M, Paim J, Bastos F, Almeida C, Bahia L, Travassos C, Reichenheim M, Barros FC. Health conditions and health policy innovations in Brazil: The way forward. Lancet. 2011;377:2042–53.CrossRefPubMed Victora CG, Barreto M, Do Carmo Leal M, Monteiro CA, Ines-Schmidt M, Paim J, Bastos F, Almeida C, Bahia L, Travassos C, Reichenheim M, Barros FC. Health conditions and health policy innovations in Brazil: The way forward. Lancet. 2011;377:2042–53.CrossRefPubMed
9.
go back to reference McWilliams A, Siegel DS, Wright PM. Corporate social responsibility: Strategic implications. J Manag Stud. 2006;43(1):1–18.CrossRef McWilliams A, Siegel DS, Wright PM. Corporate social responsibility: Strategic implications. J Manag Stud. 2006;43(1):1–18.CrossRef
10.
go back to reference Smith NC. Corporate Social Responsibility: whether or how? Calif Manage Rev. 2003;45(4):52–76.CrossRef Smith NC. Corporate Social Responsibility: whether or how? Calif Manage Rev. 2003;45(4):52–76.CrossRef
11.
go back to reference Porter ME, Kramer MR. Strategy and society: the link between competitive advantage and corporate social responsibility. Harv Bus Rev. 2006;12:78–92. Porter ME, Kramer MR. Strategy and society: the link between competitive advantage and corporate social responsibility. Harv Bus Rev. 2006;12:78–92.
12.
go back to reference Hogerzeil HV, Javasree KI, Urlings L, Prasad T, Brewer S. Is the pharmaceutical industry improving with regard to access to essential medicines? Lancet Glob Health. 2014;2(3):e139–40.CrossRefPubMed Hogerzeil HV, Javasree KI, Urlings L, Prasad T, Brewer S. Is the pharmaceutical industry improving with regard to access to essential medicines? Lancet Glob Health. 2014;2(3):e139–40.CrossRefPubMed
13.
go back to reference United Nations. World Population Prospects: The 2015 Revision. New York: United Nations; 2015. United Nations. World Population Prospects: The 2015 Revision. New York: United Nations; 2015.
15.
go back to reference Ministry of Health, Lei 8,080. Dispõe sobre as condições para a promoção, proteção e recuperação da saúde, a organização e o funcionamento dos serviços correspondentes e dá outras providências. 19 Sept 1990. Brasilia. http://conselho.Saúde.gov.br/legislacao/lei8080_190990.htm. Accessed 20 Jul 2016. Ministry of Health, Lei 8,080. Dispõe sobre as condições para a promoção, proteção e recuperação da saúde, a organização e o funcionamento dos serviços correspondentes e dá outras providências. 19 Sept 1990. Brasilia. http://​conselho.​Saúde.​gov.​br/​legislacao/​lei8080_​190990.​htm.​ Accessed 20 Jul 2016.
16.
go back to reference Almeida C, Travassos C, Porto S, Labra ME. Health sector reform in Brazil: a case study of inequity. Int J Health Serv. 2000;30(1):129–62.CrossRefPubMed Almeida C, Travassos C, Porto S, Labra ME. Health sector reform in Brazil: a case study of inequity. Int J Health Serv. 2000;30(1):129–62.CrossRefPubMed
17.
go back to reference PAHO, Pan American Health Organization, Brazil: Health Systems and Services Profile. Brasilia, Brazil: PAHO; 2008. PAHO, Pan American Health Organization, Brazil: Health Systems and Services Profile. Brasilia, Brazil: PAHO; 2008.
18.
go back to reference Nunn A. The Politics & History of AIDS Treatment in Brazil. New York: Springer Science; 2009.CrossRef Nunn A. The Politics & History of AIDS Treatment in Brazil. New York: Springer Science; 2009.CrossRef
19.
go back to reference Almeida G, Sarti FV, Ferreira FF, Diaz MDM, Campino ACC. Analysis of the evolution and determinants of income-related inequalities in the Brazilian health system, 1998–2008. Equity Health Syst. 2013;2:90–7. Almeida G, Sarti FV, Ferreira FF, Diaz MDM, Campino ACC. Analysis of the evolution and determinants of income-related inequalities in the Brazilian health system, 1998–2008. Equity Health Syst. 2013;2:90–7.
20.
go back to reference Vieira FS, Zucchi P. Resource allocation for pharmaceutical procurement in the Brazilian Unified Health System. Rev Saude Publica. 2011;45(5):1–7.CrossRef Vieira FS, Zucchi P. Resource allocation for pharmaceutical procurement in the Brazilian Unified Health System. Rev Saude Publica. 2011;45(5):1–7.CrossRef
22.
go back to reference Bertoldi AD, Helfer AP, Cmargao AL, Noemia ULT, Kanavos P. Is the Brazilian pharmaceutical policy ensuring population access to essential medicines? Glob Health. 2012;8:6.CrossRef Bertoldi AD, Helfer AP, Cmargao AL, Noemia ULT, Kanavos P. Is the Brazilian pharmaceutical policy ensuring population access to essential medicines? Glob Health. 2012;8:6.CrossRef
25.
go back to reference Ministry of Health. National Drug Policy (Politíca Naciona de Medicatmentos), Portaria 3.916, 30 October 1998, Brasilia; 1998. http://bvsms.Saúde.gov.br/bvs/Saúdelegis/gm/1998/prt3916_30_10_1998.html. Ministry of Health. National Drug Policy (Politíca Naciona de Medicatmentos), Portaria 3.916, 30 October 1998, Brasilia; 1998. http://​bvsms.​Saúde.​gov.​br/​bvs/​Saúdelegis/​gm/​1998/​prt3916_​30_​10_​1998.​html.​
33.
go back to reference Emmerick ICM, Do Nascimento JM, Pereira MA, Luiza VL, Ross-Degnan D, ISAUM-BR Collaborative Group. Farmacia Popular program: changes in geographic accessibility of medicines during ten years of a medicine subsidy policy in Brazil. J Pharm Policy Pract. 2015;8:10. doi:10.1186/s40545-015-0030-x.CrossRefPubMedPubMedCentral Emmerick ICM, Do Nascimento JM, Pereira MA, Luiza VL, Ross-Degnan D, ISAUM-BR Collaborative Group. Farmacia Popular program: changes in geographic accessibility of medicines during ten years of a medicine subsidy policy in Brazil. J Pharm Policy Pract. 2015;8:10. doi:10.​1186/​s40545-015-0030-x.CrossRefPubMedPubMedCentral
34.
go back to reference Bertoldi AD, Barros AJD, Camargo AL, Hallal PC, Vandoros S, Wagner A, Ross-Degnan D. Household ExpendituresforMedicines andtheRole of Free Medicines in the Brazilian Public Health System. Am J Public Health. 2011;5:916–21.CrossRef Bertoldi AD, Barros AJD, Camargo AL, Hallal PC, Vandoros S, Wagner A, Ross-Degnan D. Household ExpendituresforMedicines andtheRole of Free Medicines in the Brazilian Public Health System. Am J Public Health. 2011;5:916–21.CrossRef
35.
go back to reference Guimaraes R, Santos LMP, Angulo-Tuesta A, Serruya SJ. Defining and implementing a national policy for science, technology, and innovation in health: Lessons from the Brazilian experience. Cadernos Saude Publica. 2006;9:1775–94. Guimaraes R, Santos LMP, Angulo-Tuesta A, Serruya SJ. Defining and implementing a national policy for science, technology, and innovation in health: Lessons from the Brazilian experience. Cadernos Saude Publica. 2006;9:1775–94.
37.
go back to reference Gadelha, CAG. Development, health-industrial complex and industrial policy. Revista de Saúde Pública, 2006; 40, special issue, 11–23. https://dx.doi.org/10.1590/S0034-89102006000400003. Accessed 12 Dec 2016. Gadelha, CAG. Development, health-industrial complex and industrial policy. Revista de Saúde Pública, 2006; 40, special issue, 11–23. https://​dx.​doi.​org/​10.​1590/​S0034-8910200600040000​3. Accessed 12 Dec 2016.
Metadata
Title
Corporate social responsibility to improve access to medicines: the case of Brazil
Authors
Halla Thorsteinsdóttir
Natasha Ovtcharenko
Jillian Clare Kohler
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2017
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/s12992-017-0235-7

Other articles of this Issue 1/2017

Globalization and Health 1/2017 Go to the issue